SIRPant Immunotherapeutics develops an approach to elicit tumor-specific T-cells through one of two alternative means: in vivo or ex vivo. T cells are generated in vivo by administering proprietary activated autologous macrophages that activate tumoricidal T Cells, Neutrophils, and Natural Killer Cells whilst curtailing the activity of Tregs,MDSCs, IL-10 and TGFβ. T cells are generated ex vivo by the in vitro expansion of tumor-infiltrating T lymphocytes (TIL). Both in vivo and ex vivo methods result in a polyclonal immune response against multiple tumor antigens. The therapy has broad applicability for unmet needs in the treatment of solid tumors.

Biotechnology

Health Care

Therapeutics

SIRPant Immunotherapeutics

Org chart

Teams

Similar companies